Pilot Study of OMEGA-3 and Vitamin D in High-Dose in Type I Diabetic Patients

Inclusion Criteria: Patients must meet all of the following criteria to be eligible to participate in this study: * Subject must be able to understand and provide informed consent. * Males and females, 6-17 years for children and 18-65 years of age for adult group. * For new onset T1D - from onset to 6 months (180 days) post-diagnosis at the time of randomization. * For established T1D - At least 6 months and up to 10 years from the diagnosis at the time of randomization. * Affected by T1D, according to ADA standard criteria, and confirmed by positivity of at least one T1D-associated autoantibody, to GAD65, IA-2, ZnT8, or insulin autoantibody (if patient has been treated with insulin for less than 2 weeks). * T1D must be treated with insulin (except if participant is in Honeymoon period/phase). * Stimulated C-peptide peak level, at the baseline 1 visit MMTT, ≥ 0.2 ng/ml. * Female subjects of childbearing potential must have a negative pregnancy test upon study entry. * Adequate venous access to support study required blood draws. Exclusion Criteria: Patients must not meet any of the following criteria to be eligible to participate: * Inability or unwillingness of a participant to give written informed consent or comply with study protocol. * BMI\>30 kg/m2. * Contra-indications to any of the drugs used in the trial (as per package insert, e.g., knowledge of hypersensitivity to drugs or its excipients). * Uncompensated heart failure, fluid overload, myocardial infarction o…